PTH (Parathyroid hormone: involves in adjusting the calcium metabolism), a remedy for the osteoporosis, is the most emphasizing new medicine project in Green Cross.

Green Cross has already used the gene recombination technique to secure the technology to economically produce PTH in batch. Phase 2 clinical trial for the patients was completed successfully in Germany.

Unlike the existing preventive cure, PTH substantially restores the density of the lost bone. Decision Resource Inc., an international pharmaceutical consulting agency, has predicted that the world present osteoporosis cure market of USD 3 billion will reach USD 9 billion by 2007 according to the aging tendency of the population. For advantage in the PTH market, Green Cross has been executing all procedures from the development, pre-clinical phase to clinical phase to meet the FDA requirements.

Other than PTH, Green Cross is concentrating its core competence of R&D to world-class new medicine projects such as new concept of immune therapeutics (CTL) that selectively destroys the Hepatitis B virus-infected cells, the anti-cancer drug (Greenstatin) that inhibits the angiogenesis necessary for the proliferation of the cancer cell, the immunoregulatory agent (NP005) that inhibits the autoimmune disease and the organ transplantation rejection, and the antihemophilic factor (r-FVIII) using the gene recombination technology.